BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  BioTime Reports 2018 Second Quarter Results and Recent Corporate Accomplishments

  BioTime to receive $43 million from Juvenescence

  August 2, 2018

   · 

  25 min read
• Business

  Acceleron Reports Second Quarter 2018 Operating and Financial Results

  MEDALIST and BELIEVE Phase 3 trials met all primary and key secondary endpoint

  August 2, 2018

   · 

  11 min read
• Deals

  Tandem Diabetes Care Announces on August 2, 2018 Proposed Underwritten Public Offering of Common Stock

  Tandem Diabetes Care®, Inc. announced that it has commenced a proposed underwritten public offering of its common stock.

  August 2, 2018

   · 

  4 min read
• Business

  Cerus Corporation Reports Second Quarter 2018 Results

  Product revenue increases 62% compared to 2017

  August 2, 2018

   · 

  13 min read
• Business

  Nevro Reports Second Quarter 2018 Financial Results

  Nevro Corp. reported financial results for the three and six months ended June 30, 2018.

  August 2, 2018

   · 

  12 min read
• Business

  AMN Healthcare Announces Second Quarter 2018 Results

  Quarterly revenue of $558 million, up 14% over prior year; GAAP EPS of $0.73 and adjusted EPS of $0.83

  August 2, 2018

   · 

  42 min read
• Deals

  Nu Skin Enterprises Announces 2018 Second Quarterly Dividend

  Nu Skin Enterprises, Inc. (NYSE: NUS) today announced its board of directors has declared a quarterly cash dividend of $0.365 per share which will be paid on Sep. 12, 2018, to stockholders of record on Aug. 31, 2018.

  August 2, 2018

   · 

  1 min read
• Business

  CytoSorbents Achieves Record Total Revenue and CytoSorb Sales in the Second Quarter 2018

  Quarterly CytoSorb Sales Reach $5.2 Million, With Trailing 12-month CytoSorb Sales of $17.4 Million

  August 2, 2018

   · 

  31 min read
• Business

  Glaukos Announces Pharmaceutical Development Agreement with D. Western Therapeutics Institute, Inc.

  Collaboration with Preeminent Rho Kinase (ROCK) Inhibitor R&D Organization to Explore Novel Compounds for Glaukos’ iDoseTM Drug Delivery System

  August 2, 2018

   · 

  5 min read
• Business

  Glaukos Corporation Announces Second Quarter 2018 Financial Results

  Glaukos Corporation announced financial results for the second quarter ended June 30, 2018.

  August 2, 2018

   · 

  10 min read